Ophthalmic Mydriasis and cycloplegia for refraction
Adult: As 0.5, 1, or 2% soln: Instill 1 drop to each eye 30-60 min prior to procedure, may repeat after 5-15 min if necessary. Deeply pigmented eyes may require higher strength. Apply pressure over the nasolacrimal sac for 2-3 min after instillation to minimize absorption. Child: As 0.5 or 1% soln: 3 mth to 12 yr Instill 1 drop of 1% soln to each eye 30-60 min prior to procedure; >12 yr Instill 1 drop of 0.5% soln to each eye 30-60 min prior to procedure, may repeat after 5-10 min if necessary. Apply pressure over the nasolacrimal sac for 2-3 min after instillation to minimize absorption. Observe for 45 min after instillation.
Ophthalmic Iritis, Uveitis
Adult: As 0.5 or 1% soln: Instill 1 drop onto the affected eye(s) 6-8 hrly. Deeply pigmented eyes may require higher strength. Child: ≥3 mth Same as adult dose.
Confirmed or suspected narrow-angle glaucoma.
Patient w/ Down syndrome. Debilitated patients. Childn w/ spastic paralysis or brain damage. Pregnancy and lactation.
Significant: Transient increase in intraocular pressure, ocular irritation and burning sensation, CNS disturbance, psychotic reactions. Nervous: Insomnia, drowsiness, ataxia, hallucination, hyperactivity, incoherent speech, restlessness, seizure. CV: Tachycardia. Ophthalmologic: Accommodation disturbance, intolerance to bright light, stinging, blurring of vision, punctal stenosis. Dermatologic: Burning sensation of the skin.
May interfere w/ ocular antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Description: Cyclopentolate is a tertiary amine antimuscarinic agent. It reversibly blocks the action of acetylcholine resulting in relaxation of innervated iris sphincter muscle producing mydriasis. Additionally, it also paralyzes the ciliary muscle of the lense producing cycloplegia. Onset: Max: Mydriasis: Approx 30-60 min. Cycloplegia: 25-75 min. Duration: Mydriasis: Approx 24 hr. Cycloplegia: 6-24 hr. Pharmacokinetics: Absorption: May be systemically absorbed by transcorneal absorption.
Store between 20-25°C. Protect from light. Do not freeze.
S01FA04 - cyclopentolate ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.
Anon. Cyclopentolate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/07/2017.Buckingham R (ed). Cyclopentolate Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/07/2017.Cyclopentolate Solution/Drops (Akorn, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/07/2017.Joint Formulary Committee. Cyclopentolate Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/07/2017.McEvoy GK, Snow EK, Miller J et al (eds). Cyclopentolate Hydrochloride (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/07/2017.